The rationale for screening and surveillance of Barrett's metaplasia

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 5, 2006, Pages 829-842

  Wani, Sachin ^a   Sharma, Prateek ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's oesophagus; oesophageal adenocarcinoma; screening and surveillance

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CANCER SURVIVAL; CAPSULE ENDOSCOPY; CHROMOENDOSCOPY; CLINICAL PRACTICE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; ENDOSCOPIC BIOPSY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; EVIDENCE BASED MEDICINE; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; MEDICAL INFORMATION; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; STANDARDIZATION; SURVIVAL RATE; TIME; VALIDATION PROCESS;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; MASS SCREENING; METAPLASIA; POPULATION SURVEILLANCE;

EID: 33748689297     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.03.009     Document Type: Article

References (58)

1. Blot W.J., and McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Oncol 26 (1999) 2-8
2. Brown L.M., and Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 11 (2002) 235-256
3. Eloubeide M.A., Mason A.C., Desmond R.A., et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol 98 (2003) 1627-1633
4. Sharma P., McQuaid K., Dent J., et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127 (2004) 310-330
5. Falk G.W., Ours T.M., and Richter J.E. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 52 (2000) 197-203
6. Sampliner R.E. Practice parameters committee of the ACG. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1895
7. Sampliner R.E. Epidemiology, pathophysiology, and treatment of Barrett's esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am 89 (2005) 293-312
8. Winters C.J., Spurling T.J., Chobanian S.J., et al. Barrett's esophagus. A prevalent, occult complication of gastrooesophageal reflux disease. Gastroenterology 92 (1987) 118-124
9. Lieberman D.A., Oehlke M., and Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology outcomes research group in endoscopy. Am J Gastroenterol 92 (1997) 1293-1297
10. Chak A., Lee T., Kinnard M.F., et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 51 (2002) 323-328
11. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129 (2005) 1825-1831
12. Rex D.K., Cummings O.W., Shaw M., et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125 (2003) 1670-1677
13. Cameron A.J., and Lomboy C. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103 (1992) 1241-1245
14. Eloubeide M.A., and Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease. J Clin Gastroenterol 33 (2001) 306-309
15. Soni A., Sampliner R.E., and Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?. Am J Gastroenterol 95 (2000) 2086-2093
16. Inadomi J.M., Sampliner R.E., Lagergren J., et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138 (2003) 176-186
17. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed for 4.8 years. Am J Gastroenterol 92 (1999) 212-215
18. Sharma P., Reker D., Falk G., et al. Progression of Barrett's esophagus to high-grade dysplasia and cancer-preliminary results of the Barrett's esophagus study trial. Gastroenterology 120 (2001) A-16
19. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
20. Pohl H., and Welch G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
21. Anderson L.A., Murray L.J., Murphy S.J., et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 52 (2003) 1081-1084
22. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
23. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122 (2002) 26-33
24. Shaheen N.J., Dulai G.S., Ascher B., et al. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 100 (2005) 577-580
25. Van Sandick J.W., van Lanschot J.J.B., Kuiken B.W., et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43 (1998) 216-222
26. Streitz J.M., Andrews C.W., and Ellis F.H. Endoscopic surveillance of Barrett's esophagus. Does it help?. J Thorac Cardiovasc Surg 105 (1993) 383-387
27. Corley D.A., Levin T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinoma: a population-based study. Gastroenterology 122 (2002) 633-640
28. Cooper G.S. Endoscopic screening and surveillance for Barrett's esophagus: can claims data determine its effectiveness?. Gastrointest Endosc 57 (2003) 914-915
29. Peters J.H., Clark G.W., Ireland A.P., et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 108 (1994) 813-821
30. Van der Burg A., Dees J., Hop W.C., et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39 (1996) 5-8
31. Macdonald C.E., Wicks A.C., and Playford R.J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 321 (2000) 1252-1255
32. McKenna B.J., and Appelman H.D. Dysplasia can be a pain in the gut. Pathology 34 (2002) 518-528
33. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19 (1988) 166-178
34. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol 32 (2001) 368-378
35. Ormsby A.H., Petras R.E., Henricks W.H., et al. Interobserver variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51 (2002) 671-676
36. Collard J.M. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am 12 (2002) 77-92
37. Levine D.S., Haggitt R.C., Blount P.L., et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105 (1993) 40-50
38. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 (2001) 1607-1619
39. Sharma P., Falk G., Weston A.P., et al. Natural history of LGD, an infrequent finding which usually regresses: preliminary results from the Barrett's esophagus study. Gastroenterology 122 (2002) 156
40. Skacel M., Petras R.E., Gramlich T.L., et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95 (2000) 3383-3387
41. Sharma P. Low-grade dysplasia in Barrett's esophagus. Gastroenterology 127 (2004) 1233-1238
42. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression of cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
43. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120 (2001) 1630-1639
44. Overholt B., Lightdale C., Wang K., et al. International, multicenter, partially blinded, randomized study of the efficacy of PDT using POR for the ablation of HGD in Barrett's esophagus: results of 24-month follow-up. Gastroenterology 124 (2003) A20
45. Provenzale D., Schmitt C., and Wang J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94 (1999) 2043-2053
46. Miros M., Kerlin P., and Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 32 (1991) 1441-1446
47. Weston A.P., Badr A.S., and Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 94 (1999) 3413-3419
48. Polkowski W., van Lanschot J.J., Kate F.J., et al. The value of p53 and Ki67 as markers for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 4 (1995) 163-171
49. Morales C.P., Souza R.F., and Spechler S.J. Hallmarks of cancer progression in Barrett's esophagus. Lancet 360 (2002) 1587-1589
50. Buskens C.J., Van Rees B.P., Sivula A., et al. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122 (2002) 1800-1807
51. Tselepis C., Perry I., Dawson C., et al. Tumor necrosis factor-alpha in Barrett's esophagus: a potential novel mechanism of action. Oncogene 21 (2002) 6071-6081
52. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increase risk for neoplastic progression. Am J Gastroenterol 96 (2001) 2839-2848
53. Eliakim R., Sharma V.K., Yassin K., et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 39 (2005) 572-578
54. Falk G.W., Chittajallu R., Goldblum J.R., et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 112 (1997) 1787-1797
55. Connor M.J., and Sharma P. Chromoendoscopy and magnification endoscopy in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 (2003) 269-277
56. Canto M.I., Setrakian S., Petras R., et al. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 44 (1996) 1-6
57. Sharma P., Weston A.P., Topalovski M., et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gut 52 (2003) 24-27
58. Sharma P, Bansal A, Mathur S et al. The utility of a narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc [in press].